Is NCT05800015 recruiting?

NCT05800015 is currently active, not recruiting. This lung cancer study is not actively recruiting at this time.

What is the status of NCT05800015?

NCT05800015 is currently active, not recruiting. This is a Clinical Trial trial for lung cancer sponsored by Regeneron Pharmaceuticals. Status verified Jan 22, 2026 via ClinicalTrials.gov.

Where is NCT05800015 enrolling participants?

NCT05800015 has 29 active sites including Tucson, Arizona; Yuma, Arizona; Cerritos, California and 26 more locations.

Who is eligible for NCT05800015?

This lung cancer trial is targeting 950 participants. Detailed eligibility criteria including age requirements and medical history are listed on this page.

Who can participate in this Lung Cancer study?

Eligibility varies by study, but generally includes adults diagnosed with Lung Cancer who meet specific medical criteria. Complete the interest form above to learn if you may qualify.

Is the study available in Tucson, Arizona?

Yes! This study has active research sites in Tucson, Yuma, Cerritos. When you express interest, you'll be connected with the site nearest to you.

What are the benefits of joining a clinical trial for Lung Cancer?

Participants often receive: access to new treatments before they're widely available, close monitoring by medical professionals, study-related care at no cost, and the opportunity to contribute to medical research.

⚡Your ready-to-use recruitment solution: IRB-compliant, SEO-optimized website that automatically routes qualified patient leads to your clinical study (14-day free trial, then $44/mo)

NCT05800015 RECRUITINGIRB Ready

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Express Your Interest Today

Interested in learning more? Complete the form below.

First Name *

Last Name *

Email Address *

Phone Number *

ZIP Code *

Age Range *

Preferred Location

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

No-Cost Study Care
Advance Medical Science
Contribute to groundbreaking research
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel (varies by study)
Help Others
Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

1Submit this form
2Phone screening
3In-person assessment if eligible
4Begin participation

About This Study

This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin.

Who Can Participate

Inclusion Criteria

Patients with non-squamous or squamous histology NSCLC with stage IIIB or stage IIIC disease who are not candidates for surgical resection or definitive chemoradiation per investigator assessment or stage IV (metastatic disease), who received no prior systemic treatment for recurrent or metastatic NSCLC. 2. Availability of an archival or on-study formalin-fixed, paraffin-embedded (FFPE) tumor tissue sample, without intervening therapy between biopsy collection and screening as described in the protocol 3. For enrollment in phase 2, patients should have PD-L1, expression results (regardless of expression level) determined by a College of American Pathologists (CAP)/Clinical Laboratory Improvement Amendments (CLIA) (or equivalently licensed, according to local regulations) accredited laboratory, as described in the protocol. For enrollment in phase 3, patients should have a valid PD-L1 result, regardless of expression level, using an assay as performed by a ce

❓ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

📋

Study Type

INTERVENTIONAL

👥

Target Enrollment

950 participants

⚧

Gender

ALL

🏢

Sponsor

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

🔒 Secure · 🏥 Expert Care

Find More Lung Cancer Trials by City

Browse all lung cancer clinical trials in these cities — not just this study.

Tucson, Arizona Yuma, Arizona Cerritos, California Fullerton, California Orange, California Rancho Mirage, California

Browse More Trials by Condition

Lung Cancer Trials Small Cell Lung Cancer Trials Non-Small Cell Lung Cancer Trials All Conditions →

Looking for Lung Cancer Treatment in Tucson?

Join others in Arizona exploring innovative treatment options through clinical research

Lung Cancer Treatment Options in Tucson, Arizona

If you're searching for Lung Cancer treatment in Tucson, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Tucson, Yuma, Cerritos and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Lung Cancer. All study-related care is provided at no cost to participants.

Local Sites

3 locations in Arizona

Now Enrolling

Up to 950 participants

Quick Start

Screening available now

Why Consider a Clinical Trial for Lung Cancer?

Potential Benefits

✓Access to new treatment approaches before public availability
✓Close monitoring by experienced medical professionals
✓Study-related care provided at no cost
✓Contribute to medical research for Lung Cancer

What to Expect

→Initial screening to determine eligibility
→Regular check-ups and monitoring visits
→Possible compensation for time and travel
→You can withdraw at any time

Frequently Asked Questions About This Lung Cancer Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT05800015. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.